5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy- | 97850-14-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-
• 英文别名: (5E,8E,11E,13E,17E)-15-hydroxyicosa-5,8,11,13,17-pentaenoic acid
• CAS: 97850-14-1
• 化学式: C₂₀H₃₀O₃
• 分子量: 318.4
• InChiKey: WLKCSMCLEKGITB-WCRDCVHYSA-N

物化性质

• 沸点：
  488.0±45.0 °C(Predicted)
• 密度：
  0.997±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Compositions comprising 15-OHEPA and methods of using the same
  申请人：Dignity Sciences Limited

  公开号：EP2762143A1

  公开（公告）日：2014-08-06

  The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.

  本发明涉及通过服用 15-OHEPA 来治疗脂肪肝疾病，如非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）及其后遗症的组合物、制剂和方法。
• COMPOSITIONS COMPRISING 15-OHEPA AND METHODS OF USING THE SAME
  申请人：Dignity Sciences Limited

  公开号：EP3058943A1

  公开（公告）日：2016-08-24

  The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.

  本发明涉及通过服用 15-OHEPA 来治疗脂肪肝疾病，如非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）及其后遗症的组合物、制剂和方法。
• PHARMACEUTICALLY ACCEPTABLE SALTS OF POLYUNSATURATED HYDROXY FATTY ACIDS
  申请人：DS Biopharma Limited

  公开号：EP3546446A1

  公开（公告）日：2019-10-02

  The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.

  本公开提供了药学上可接受的 15-脂氧合酶产品（如 15-HETrE 赖氨酸盐）的稳定盐形式、包含其的组合物以及制造和使用其的方法。
• COMPOSITIONS COMPRISING 15-HEPE FOR USE IN TREATING OR PREVENTING NEUROLOGIC DISEASE
  申请人：Affimune Limited

  公开号：EP3861995A1

  公开（公告）日：2021-08-11

  The present disclosure provides compositions comprising 15-HEPE for use in treating and/or preventing neurological diseases in a subject in need thereof.

  本公开提供了包含 15-HEPE 的组合物，用于治疗和/或预防有需要的受试者的神经系统疾病。
• COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING SAME
  申请人：Afimmune Limited

  公开号：EP3988101A1

  公开（公告）日：2022-04-27

  The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing fibrosis in a subject in need thereof.

  本公开提供了包含 15-HEPE 的组合物以及使用该组合物治疗和/或预防有需要的受试者纤维化的方法。